However, an overview [76] of that monoclonal antibody directed against IL-33 itself and another (astegolimab) directed against its ST2 receptor [77] reiterated that while this ligand-receptor signaling is associated with AD, later phase trials of each have not seen improved clinical outcomes [78,79]. This evidence concerns the gene IL33 and Alzheimer disease.